A phase I/II clinical trial of annamycin for the treatment of relapsed or refractory acute myeloid leukemia

Trial Profile

A phase I/II clinical trial of annamycin for the treatment of relapsed or refractory acute myeloid leukemia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Annamycin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Moleculin
  • Most Recent Events

    • 22 Aug 2017 According to a Moleculin Biotech media release, the company is planning to meet with the European Medicines Agency (EMA) on Wednesday, August 30, 2017 to discuss Clinical Trial Authorization for this study .
    • 14 Aug 2017 According to a Moleculin Biotech media release, the company made an announcement that IND for annamycin has become effective and they may begin clinical trials in Sep 2017.
    • 03 Aug 2017 According to a Moleculin Biotech media release, the company has selected Bioscience SA CRO to begin identifying and preparing clinical testing sites in Poland for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top